Epigenomics AG
EPGNF
Other OTC1.12
USD
- -
- -
ISIN
DE000A37FT41
CUSIP
G3163R109
Return %
Stock
S&P500
1Y
- -
17.85
3Y
37.25
64.56
5Y
-22.22
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jason Wouhra
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- ZiegelhAeuser Landstrasse 3 Heidelberg BE Germany 69120
- IPO Date
- Dec 31, 2010
- Website
- epigenomics.com
- Similar Companies
- Business
- Epigenomics AG is a Germany-based holding company dedicated to managing its own assets, acquiring, holding and disposing of investments in companies in Germany and abroad, particularly in the field of minimally invasive blood tests for cancer detection, as well as investing in other assets. Founded in 1998 and headquartered in Berlin, Germany, with a former subsidiary Epigenomics Inc. in Seattle, Washington, USA, the company previously operated as a molecular diagnostics firm focused on developing and commercializing in vitro diagnostic liquid biopsy tests using DNA methylation biomarkers for cancer screening, early detection and diagnosis. Its core historical products included Epi proColon, a blood-based test measuring SEPT9 gene promoter methylation for colorectal cancer screening; Epi proLung, a test assessing SHOX2 gene methylation in bronchial lavage fluid to aid lung cancer diagnosis; and services spanning biomarker discovery, assay development, regulatory approval support and ISO 13485-compliant IVD manufacturing for partners. In 2023, Epigenomics AG sold nearly all its operating assets, including patents and biobank, to U.S.-based New Day Diagnostics LLC in a transaction approved by shareholders in September 2023 and closed in October 2023, receiving initial cash payments totaling up to USD 1.8 million, an equity interest in the acquirer, potential milestone payments up to USD 8.0 million tied to Epi proColon Next-Gen development, and royalties on commercialization extending to 2043. The divestiture shifted the company from active diagnostics operations to a pure holding structure, with no significant ongoing business activities thereafter. Recent financial updates include a reduced H1 2025 net loss of 204 thousand EUR versus 796 thousand EUR in H1 2024, minimal revenues of 4 thousand EUR, and negative equity of 11.065 million EUR as of June 30, 2025, with guidance maintained for a full-year 2025 net loss of 0.1-0.5 million EUR; the company lists on the Frankfurt Stock Exchange General Standard under ticker ECX (ISIN DE000A37FT41).